July 08, 2026 —
A new study published in Nature Biotechnology describes a gene therapy strategy that combines engineered AAV5 vectors with delivery through the brain’s glymphatic transport system to distribute therapeutic genes broadly across the brain while preferentially targeting human glial cells.
The approach addresses two major barriers in neurological gene therapy: reaching therapeutic targets protected by the blood-brain barrier and reducing unwanted exposure to peripheral organs. By using the brain’s natural cerebrospinal fluid transport pathways, the researchers were able to deliver engineered viral vectors throughout brain tissue while limiting systemic biodistribution.
The study was led by Steve Goldman, MD, PhD, co-director of the University of Rochester Medicine Center for Translational Neuromedicine. Goldman’s laboratory has long focused on the role of glial cells, the support cells of the nervous system that contribute to myelin production, neuronal health, and brain homeostasis. Increasing evidence suggests that glial dysfunction plays an important role in multiple neurological diseases, including Huntington’s disease, multiple sclerosis, and inherited white matter disorders.
To develop glia-targeted vectors, the research team engineered a library of modified AAV5 capsids. Each variant carried small changes to the viral outer shell, which influences cell tropism. The vectors were screened in mice whose brains had been transplanted with human glial progenitor cells, enabling selection under biologically relevant in vivo conditions.
Using a genetic tracking system, the researchers identified AAV variants that preferentially infected human glial progenitor cells and their descendants, including astrocytes and oligodendrocytes. The selected vectors showed strong preference for human glial cells while demonstrating limited infection of peripheral tissues.
The delivery strategy was equally important. The researchers administered the engineered AAVs into the cisterna magna, a cerebrospinal fluid-filled compartment at the base of the brain, and used hypertonic treatment to enhance fluid uptake into the glymphatic network. This enabled the vectors to spread broadly through brain tissue while largely bypassing the blood-brain barrier.
Because vector exposure was concentrated in the central nervous system, the approach also reduced delivery to peripheral organs such as the liver, a common safety concern in systemic AAV gene therapy. This may provide a more targeted route for treating neurological diseases where broad brain distribution is required.
The platform may be particularly relevant for diseases involving glial dysfunction or white matter pathology. Potential applications include pediatric lysosomal storage diseases, inherited leukodystrophies, multiple sclerosis, age-related white matter loss, Huntington’s disease, and other neurodegenerative disorders in which glial cells contribute to disease progression.
The study also provides a framework for discovering disease- and cell-type-specific vectors. The researchers are exploring the use of artificial intelligence to design viral capsids with desired targeting characteristics, potentially accelerating the development of next-generation CNS gene therapies.
While the work remains preclinical, it highlights a promising direction for neurological gene therapy: pairing targeted AAV capsid engineering with delivery through the brain’s own fluid transport system. If successfully translated, this strategy could help expand gene therapy beyond localized CNS delivery toward broader and more selective treatment of complex brain disorders.
